FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

PJ Burke

Research Profile

Disorders

Chemicals & Drugs

Procedures

Anatomy

Physiology

Cell Divisions

Co-author Network

Publications

TOP 3
E M Sotomayor; Steven Piantadosi; Carole B Miller; Judith E Karp; Richard J Jones; S D Rowley; Scott H Kaufmann; Hayden Braine; PJ Burke; Steven D Gore
Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.
Phyllis A Svingen; Judith E Karp; Stan Krajewski; Peter W Mesner; Steven D Gore; PJ Burke; John C Reed; Y A Lazebnik; Scott H Kaufmann
Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia.
Steven D Gore; Eric K Rowinsky; Carole B Miller; Constance A Griffin; Tian Ling Chen; Michael J Borowitz; Ross C Donehower; Kathleen Burks; Deborah K Armstrong; PJ Burke; Michael R Grever; Scott H Kaufmann
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of PJ Burke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2002: E M Sotomayor; Steven Piantadosi; Carole B Miller; Judith E Karp; Richard J Jones; S D Rowley; Scott H Kaufmann; Hayden Braine; PJ Burke; Steven D Gore
Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.
Leukemia research 2002;26(5):461-71.
2000: Phyllis A Svingen; Judith E Karp; Stan Krajewski; Peter W Mesner; Steven D Gore; PJ Burke; John C Reed; Y A Lazebnik; Scott H Kaufmann
Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia.
Blood 2000;96(12):3922-31.
1998: Steven D Gore; Eric K Rowinsky; Carole B Miller; Constance A Griffin; Tian Ling Chen; Michael J Borowitz; Ross C Donehower; Kathleen Burks; Deborah K Armstrong; PJ Burke; Michael R Grever; Scott H Kaufmann
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2677-89.
1998: B Douglas Smith; B J Bambach; Milada S Vala; Jamie P Barber; C Enger; Robert A Brodsky; PJ Burke; Steven D Gore; Richard J Jones
Inhibited apoptosis and drug resistance in acute myeloid leukaemia.
British journal of haematology 1998;102(4):1042-9.
1998: Steven D Gore; PJ Burke; Li-Jun Weng
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Leukemia & lymphoma 1998;29(3-4):339-50.
1998: Scott H Kaufmann; Steven D Gore; Carole B Miller; Richard J Jones; L A Zwelling; E Schneider; PJ Burke; Judith E Karp
Topoisomerase II and the response to antileukemic therapy.
Leukemia & lymphoma 1998;29(3-4):217-37.
1998: Scott H Kaufmann; Judith E Karp; Phyllis A Svingen; Stan Krajewski; PJ Burke; Steven D Gore; John C Reed
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.
Blood 1998;91(3):991-1000.
1996: Scott H Kaufmann; Steven D Gore; L Letendre; Phyllis A Svingen; Timothy J Kottke; C A Buckwalter; Richard J Jones; Louise B. Grochow; PJ Burke; Ross C Donehower; Eric K Rowinsky
Factors affecting topotecan sensitivity in human leukemia samples.
Annals of the New York Academy of Sciences 1996;803():128-42.
1995: Steven D Gore; Li-Jun Weng; Richard J Jones; K Cowan; M Zilcha; Steven Piantadosi; PJ Burke
Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(3):295-303.
1994: Steven D Gore; Li-Jun Weng; PJ Burke
Identification of growth factor-responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation.
Leukemia 1994;8(11):1854-63.
1994: Eric K Rowinsky; Alex A. Adjei; Ross C Donehower; Steven D Gore; Richard J Jones; PJ Burke; Y C Cheng; Louise B. Grochow; S H Kaufmann
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2193-203.
1994: Steven D Gore; A D Donnenberg; B A Zehnbauer; Li-Jun Weng; PJ Burke
Granulocyte-macrophage colony-stimulating factor (GM-CSF), given concurrently with induction therapy for acute myelogenous leukemia (AML), augments the syndrome of T-lymphocyte recovery.
Leukemia 1994;8(3):409-19.
1993: Steven D Gore; Li-Jun Weng; PJ Burke
Validation of flow-cytometric determination of Ki67 expression as a measure of growth factor response in acute myelogenous leukemia.
Experimental hematology 1993;21(13):1702-8.
1991: Anita L Hawkins; Carole B Miller; PJ Burke; Constance A Griffin
Evolution of a near-triploid karyotype in a secondary erythroleukemia.
Cancer genetics and cytogenetics 1991;54(1):11-20.
1991: PJ Burke
The cure of leukemia: a model for the role of humoral growth factors in cancer treatment.
Seminars in hematology 1991;28(3 Suppl 4):48-53.
1991: Barry D Nelkin; D Przepiorka; PJ Burke; E D Thomas; Stephen B Baylin
Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia.
Blood 1991;77(11):2431-4.
1990: R B Geller; Marianna Zahurak; C A Hurwitz; PJ Burke; Judith E Karp; Steven Piantadosi; Curt I Civin
Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10)
British journal of haematology 1990;76(3):340-7.
1990: Judith E Karp; PJ Burke; Ross C Donehower
Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity.
Leukemia 1990;4(8):553-6.
1990: R B Geller; R Saral; Judith E Karp; G W Santos; PJ Burke
Cure of acute myelocytic leukemia in adults: a reality.
Leukemia 1990;4(5):313-5.
1990: Richard J Jones; Saul J Sharkis; Carole B Miller; Eric K Rowinsky; PJ Burke; W S May
Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.
Blood 1990;75(6):1319-23.
1989: R B Geller; PJ Burke; Judith E Karp; RICHARD HUMPHREY; Hayden Braine; R W Tucker; M G Fox; Marianna Zahurak; L Morrell; K L Hall
A two-step timed sequential treatment for acute myelocytic leukemia.
Blood 1989;74(5):1499-506.
1989: PJ Burke; Judith E Karp; R B Geller; W P Vaughan
Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).
Leukemia 1989;3(10):692-4.
1989: Eric K Rowinsky; PJ Burke; Judith E Karp; R W Tucker; David S Ettinger; Ross C Donehower
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Cancer research 1989;49(16):4640-7.
1988: John R Wingard; D Y Chen; W H Burns; D J Fuller; Hayden Braine; A M Yeager; H Kaiser; PJ Burke; M L Graham; G W Santos
Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation.
Blood 1988;71(5):1432-7.